Magda Marcatti

3.3k total citations
55 papers, 967 citations indexed

About

Magda Marcatti is a scholar working on Hematology, Oncology and Molecular Biology. According to data from OpenAlex, Magda Marcatti has authored 55 papers receiving a total of 967 indexed citations (citations by other indexed papers that have themselves been cited), including 43 papers in Hematology, 26 papers in Oncology and 16 papers in Molecular Biology. Recurrent topics in Magda Marcatti's work include Multiple Myeloma Research and Treatments (29 papers), Hematopoietic Stem Cell Transplantation (14 papers) and Cancer Treatment and Pharmacology (9 papers). Magda Marcatti is often cited by papers focused on Multiple Myeloma Research and Treatments (29 papers), Hematopoietic Stem Cell Transplantation (14 papers) and Cancer Treatment and Pharmacology (9 papers). Magda Marcatti collaborates with scholars based in Italy, United States and France. Magda Marcatti's co-authors include Fabio Ciceri, Maurilio Ponzoni, Massimo Bernardi, Claudio Bordignon, Attilio Bondanza, Chiara Bonini, Barbara Camisa, Monica Casucci, Laura Falcone and Bernhard Gentner and has published in prestigious journals such as Blood, Cancer Research and International Journal of Molecular Sciences.

In The Last Decade

Magda Marcatti

53 papers receiving 957 citations

Peers

Magda Marcatti
Shunya Arai Japan
Claudia Cocco Italy
Alison R. Sehgal United States
Anna van Rhenen Netherlands
Yao-Qi Huang United States
Rogier M. Reijmers Netherlands
Xinsheng Xie China
Mobin Karimi United States
Bin Fan United States
Abdul Hamid Bazarbachi United States
Shunya Arai Japan
Magda Marcatti
Citations per year, relative to Magda Marcatti Magda Marcatti (= 1×) peers Shunya Arai

Countries citing papers authored by Magda Marcatti

Since Specialization
Citations

This map shows the geographic impact of Magda Marcatti's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Magda Marcatti with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Magda Marcatti more than expected).

Fields of papers citing papers by Magda Marcatti

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Magda Marcatti. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Magda Marcatti. The network helps show where Magda Marcatti may publish in the future.

Co-authorship network of co-authors of Magda Marcatti

This figure shows the co-authorship network connecting the top 25 collaborators of Magda Marcatti. A scholar is included among the top collaborators of Magda Marcatti based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Magda Marcatti. Magda Marcatti is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
3.
4.
Riva, Nilo, Romina Mayra Lasagni Vitar, Marco Barbariga, et al.. (2022). Corneal and Epidermal Nerve Quantification in Chemotherapy Induced Peripheral Neuropathy. Frontiers in Medicine. 9. 832344–832344. 11 indexed citations
5.
Farina, Francesca, Sarah Marktel, Sara Mastaglio, et al.. (2022). Case Report: Invasive Fungal Infection and Daratumumab: A Case Series and Review of Literature. Frontiers in Oncology. 12. 867301–867301. 1 indexed citations
6.
Antonini, Elena, Tommaso Perini, Francesca Farina, et al.. (2022). Minimal residual disease detection by next-generation sequencing in multiple myeloma: Promise and challenges for response-adapted therapy. Frontiers in Oncology. 12. 932852–932852. 9 indexed citations
7.
Ruggeri, Annalisa, Maria Teresa Lupo Stanghellini, Sara Mastaglio, et al.. (2021). Treosulfan-Based Conditioning Regimen Prior to Allogeneic Stem Cell Transplantation: Long-Term Results From a Phase 2 Clinical Trial. Frontiers in Oncology. 11. 731478–731478. 7 indexed citations
8.
Montefusco, Vittorio, Alessandro Corso, Mónica Galli, et al.. (2020). Bortezomib, cyclophosphamide, dexamethasone versus lenalidomide, cyclophosphamide, dexamethasone in multiple myeloma patients at first relapse. British Journal of Haematology. 188(6). 907–917. 7 indexed citations
9.
Lullo, Giulia Di, Magda Marcatti, Silvia Heltai, et al.. (2019). Immunomodulatory Drugs in the Context of Autologous Hematopoietic Stem Cell Transplantation Associate With Reduced Pro-tumor T Cell Subsets in Multiple Myeloma. Frontiers in Immunology. 9. 3171–3171. 10 indexed citations
10.
Botrugno, Oronza A., Silvia Bianchessi, Desirée Zambroni, et al.. (2019). ATR addiction in multiple myeloma: synthetic lethal approaches exploiting established therapies. Haematologica. 105(10). 2440–2447. 17 indexed citations
11.
Forcina, Alessandra, Francesca Lorentino, Chiara Oltolini, et al.. (2018). Clinical Impact of Pretransplant Multidrug-Resistant Gram-Negative Colonization in Autologous and Allogeneic Hematopoietic Stem Cell Transplantation. Biology of Blood and Marrow Transplantation. 24(7). 1476–1482. 38 indexed citations
12.
Oliva, Laura, Ugo Orfanelli, Massimo Resnati, et al.. (2017). The amyloidogenic light chain is a stressor that sensitizes plasma cells to proteasome inhibitor toxicity. Blood. 129(15). 2132–2142. 60 indexed citations
13.
Castagna, Luca, Alberto Mussetti, Raynier Devillier, et al.. (2017). Haploidentical Allogeneic Hematopoietic Cell Transplantation for Multiple Myeloma Using Post-Transplantation Cyclophosphamide Graft-versus-Host Disease Prophylaxis. Biology of Blood and Marrow Transplantation. 23(9). 1549–1554. 23 indexed citations
14.
Forcina, Alessandra, Paola M. V. Rancoita, Magda Marcatti, et al.. (2017). A New Clinicobiological Scoring System for the Prediction of Infection-Related Mortality and Survival after Allogeneic Hematopoietic Stem Cell Transplantation. Biology of Blood and Marrow Transplantation. 23(12). 2151–2158. 8 indexed citations
15.
Bianco, Mimma, Anna Maria Gasparri, Barbara Colombo, et al.. (2016). Chromogranin A Is Preferentially Cleaved into Proangiogenic Peptides in the Bone Marrow of Multiple Myeloma Patients. Cancer Research. 76(7). 1781–1791. 20 indexed citations
16.
Marchica, Valentina, Fabrizio Accardi, Paola Storti, et al.. (2016). Cutaneous localization in multiple myeloma in the context of bortezomib-based treatment: how do myeloma cells escape from the bone marrow to the skin?. International Journal of Hematology. 105(1). 104–108. 11 indexed citations
17.
Belloni, Daniela, Magda Marcatti, Maurilio Ponzoni, et al.. (2014). Angiopoietin-2 in Bone Marrow milieu promotes Multiple Myeloma-associated angiogenesis. Experimental Cell Research. 330(1). 1–12. 16 indexed citations
18.
Larocca, Alessandra, Vittorio Montefusco, Sara Bringhen, et al.. (2013). Pomalidomide, cyclophosphamide, and prednisone for relapsed/refractory multiple myeloma: a multicenter phase 1/2 open-label study. Blood. 122(16). 2799–2806. 66 indexed citations
19.
Corradini, Paolo, Corrado Tarella, Marco Bregni, et al.. (2000). Allografting for patients with advanced hematological malignancies: non-myeloablative conditioning followed by the reinfusion of lymphocytes engineered with hsv thymidine kinase gene. Blood. 96. 1 indexed citations
20.
Losa, Marco, Maria Rosa Terreni, Moreno Tresoldi, et al.. (1992). Solitary plasmacytoma of the sphenoid sinus involving the pituitary fossa: A case report and review of the literature. Surgical Neurology. 37(5). 388–393. 27 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Shunya Arai Breakdown of academic impact, for papers by Claudia Cocco Breakdown of academic impact, for papers by Alison R. Sehgal Breakdown of academic impact, for papers by Anna van Rhenen Breakdown of academic impact, for papers by Yao-Qi Huang Breakdown of academic impact, for papers by Rogier M. Reijmers Breakdown of academic impact, for papers by Xinsheng Xie Breakdown of academic impact, for papers by Mobin Karimi Breakdown of academic impact, for papers by Bin Fan Breakdown of academic impact, for papers by Abdul Hamid Bazarbachi
Rankless by CCL
2026